Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.

Aymonnier K, Kawecki C, Venisse L, Boulaftali Y, Christophe OD, Lenting PJ, Arocas V, de Raucourt E, Denis CV, Bouton MC.

Blood. 2019 Aug 5. pii: blood.2019000281. doi: 10.1182/blood.2019000281. [Epub ahead of print]

PMID:
31383642
2.

Emicizumab and thrombosis: The story so far.

Makris M, Iorio A, Lenting PJ.

J Thromb Haemost. 2019 Aug;17(8):1269-1272. doi: 10.1111/jth.14556. No abstract available.

PMID:
31368220
3.

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]

4.

von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week.

Van Belle E, Vincent F, Rauch A, Casari C, Jeanpierre E, Loobuyck V, Rosa M, Delhaye C, Spillemaeker H, Paris C, Debry N, Verdier B, Vincentelli A, Dupont A, Lenting PJ, Susen S.

J Am Coll Cardiol. 2019 Mar 12;73(9):1078-1088. doi: 10.1016/j.jacc.2018.12.045. Review.

PMID:
30846101
5.

Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.

Dupont A, Soukaseum C, Cheptou M, Adam F, Nipoti T, Lourenco-Rodrigues MD, Legendre P, Proulle V, Rauch A, Kawecki C, Bryckaert M, Rosa JP, Paris C, Ternisien C, Boisseau P, Goudemand J, Borgel D, Lasne D, Maurice P, Lenting PJ, Denis CV, Susen S, Kauskot A.

Haematologica. 2019 Feb 28. pii: haematol.2018.206250. doi: 10.3324/haematol.2018.206250. [Epub ahead of print]

6.

Antibodies in the Treatment of Haemophilia A-A Biochemical Perspective.

Ferrière S, Lenting PJ.

Hamostaseologie. 2019 Feb;39(1):36-41. doi: 10.1055/s-0038-1677521. Epub 2019 Jan 29.

PMID:
30695798
7.

Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor.

Xu ER, von Bülow S, Chen PC, Lenting PJ, Kolšek K, Aponte-Santamaría C, Simon B, Foot J, Obser T, Schneppenheim R, Gräter F, Denis CV, Wilmanns M, Hennig J.

Blood. 2019 Jan 24;133(4):366-376. doi: 10.1182/blood-2018-04-843615. Epub 2018 Oct 10.

8.

Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?

Vincent F, Rauch A, Spillemaeker H, Vincentelli A, Paris C, Rosa M, Dupont A, Delhaye C, Verdier B, Robin E, Lenting PJ, Susen S, Van Belle E.

JACC Cardiovasc Interv. 2018 Sep 10;11(17):1775-1778. doi: 10.1016/j.jcin.2018.05.047. Review.

PMID:
30190067
9.

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

Muczynski V, Casari C, Moreau F, Aymé G, Kawecki C, Legendre P, Proulle V, Christophe OD, Denis CV, Lenting PJ.

Blood. 2018 Sep 13;132(11):1193-1197. doi: 10.1182/blood-2018-01-829523. Epub 2018 Jul 31.

PMID:
30064978
10.

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Casari C, Paul DS, Susen S, Lavenu-Bombled C, Harroche A, Piatt R, Poe KO, Lee RH, Bryckaert M, Christophe OD, Lenting PJ, Denis CV, Bergmeier W.

Blood Adv. 2018 Jun 26;2(12):1417-1428. doi: 10.1182/bloodadvances.2017014290.

11.

von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment.

Vincent F, Rauch A, Loobuyck V, Moussa M, Juthier F, Debry N, Jeanpierre E, Lenting PJ, Susen S, Van Belle E.

Circ Res. 2018 May 25;122(11):1499-1500. doi: 10.1161/CIRCRESAHA.118.312859. No abstract available.

PMID:
29798900
12.

Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support.

Vincent F, Rauch A, Loobuyck V, Robin E, Nix C, Vincentelli A, Smadja DM, Leprince P, Amour J, Lemesle G, Spillemaeker H, Debry N, Latremouille C, Jansen P, Capel A, Moussa M, Rousse N, Schurtz G, Delhaye C, Paris C, Jeanpierre E, Dupont A, Corseaux D, Rosa M, Sottejeau Y, Barth S, Mourran C, Gomane V, Coisne A, Richardson M, Caron C, Preda C, Ung A, Carpentier A, Hubert T, Denis C, Staels B, Lenting PJ, Van Belle E, Susen S.

J Am Coll Cardiol. 2018 May 15;71(19):2106-2118. doi: 10.1016/j.jacc.2018.02.075.

13.

VWF clearance: it's glycomplicated.

Denis CV, Lenting PJ.

Blood. 2018 Feb 22;131(8):842-843. doi: 10.1182/blood-2018-01-824904. No abstract available.

14.

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

Wohner N, Muczynski V, Mohamadi A, Legendre P, Proulle V, Aymé G, Christophe OD, Lenting PJ, Denis CV, Casari C.

Haematologica. 2018 Apr;103(4):728-737. doi: 10.3324/haematol.2017.175216. Epub 2018 Jan 11.

15.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Dec 7;130(23):2463-2468. doi: 10.1182/blood-2017-08-801662. Epub 2017 Oct 17. Review.

16.

Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

Muczynski V, Christophe OD, Denis CV, Lenting PJ.

Semin Thromb Hemost. 2017 Sep;43(6):581-590. doi: 10.1055/s-0037-1604053. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750425
17.

von Willebrand factor and inflammation.

Kawecki C, Lenting PJ, Denis CV.

J Thromb Haemost. 2017 Jul;15(7):1285-1294. doi: 10.1111/jth.13696. Review.

18.

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, Christophe OD, Lenting PJ.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1736-1740. doi: 10.1161/ATVBAHA.117.309319. Epub 2017 Jun 22.

PMID:
28642239
19.

Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi.

Martinez de Lizarrondo S, Gakuba C, Herbig BA, Repessé Y, Ali C, Denis CV, Lenting PJ, Touzé E, Diamond SL, Vivien D, Gauberti M.

Circulation. 2017 Aug 15;136(7):646-660. doi: 10.1161/CIRCULATIONAHA.117.027290. Epub 2017 May 9.

20.

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

Muczynski V, Aymé G, Regnault V, Vasse M, Borgel D, Legendre P, Bazaa A, Harel A, Loubière C, Lenting PJ, Denis CV, Christophe OD.

Blood. 2017 Apr 27;129(17):2443-2454. doi: 10.1182/blood-2016-06-724351. Epub 2017 Feb 17.

21.

Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice.

Kirschbaum M, Jenne CN, Veldhuis ZJ, Sjollema KA, Lenting PJ, Giepmans BNG, Porte RJ, Kubes P, Denis CV, Lisman T.

Liver Int. 2017 Nov;37(11):1731-1737. doi: 10.1111/liv.13386. Epub 2017 Mar 5.

PMID:
28178387
22.

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.

Pepin M, Mezouar S, Pegon J, Muczynski V, Adam F, Bianchini EP, Bazaa A, Proulle V, Rupin A, Paysant J, Panicot-Dubois L, Christophe OD, Dubois C, Lenting PJ, Denis CV.

Sci Rep. 2016 Nov 28;6:37953. doi: 10.1038/srep37953.

23.

LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex.

Fazavana JG, Muczynski V, Proulle V, Wohner N, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2016 Dec;14(12):2458-2470. doi: 10.1111/jth.13502. Epub 2016 Oct 25.

24.

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Kauskot A, Poirault-Chassac S, Adam F, Muczynski V, Aymé G, Casari C, Bordet JC, Soukaseum C, Rothschild C, Proulle V, Pietrzyk-Nivau A, Berrou E, Christophe OD, Rosa JP, Lenting PJ, Bryckaert M, Denis CV, Baruch D.

JCI Insight. 2016 Oct 6;1(16):e88643. doi: 10.1172/jci.insight.88643.

25.

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D.

Blood. 2016 Oct 20;128(16):2007-2016. doi: 10.1182/blood-2016-04-713289. Epub 2016 Sep 1. Review.

26.

Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement.

Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, Jeanpierre E, Levade M, Hurt C, Rousse N, Dally JB, Debry N, Dallongeville J, Vincentelli A, Delhaye C, Auffray JL, Juthier F, Schurtz G, Lemesle G, Caspar T, Morel O, Dumonteil N, Duhamel A, Paris C, Dupont-Prado A, Legendre P, Mouquet F, Marchant B, Hermoire S, Corseaux D, Moussa K, Manchuelle A, Bauchart JJ, Loobuyck V, Caron C, Zawadzki C, Leroy F, Bodart JC, Staels B, Goudemand J, Lenting PJ, Susen S.

N Engl J Med. 2016 Jul 28;375(4):335-44. doi: 10.1056/NEJMoa1505643.

27.

Antibody-Based Protection of von Willebrand Factor Degradation.

Lenting PJ, Denis CV, Susen S, van Belle E.

JACC Heart Fail. 2016 Jun;4(6):518. doi: 10.1016/j.jchf.2015.12.018. No abstract available.

28.

A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Adam F, Casari C, Prévost N, Kauskot A, Loubière C, Legendre P, Repérant C, Baruch D, Rosa JP, Bryckaert M, de Groot PG, Christophe OD, Lenting PJ, Denis CV.

Sci Rep. 2016 May 23;6:26306. doi: 10.1038/srep26306.

29.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.

PMID:
26791163
30.

Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.

Berrou E, Kauskot A, Adam F, Harel A, Legendre P, Lavenu Bombled C, Rothschild C, Prevost N, Christophe OD, Lenting PJ, Denis CV, Rosa JP, Bryckaert M.

PLoS One. 2015 Dec 8;10(12):e0143896. doi: 10.1371/journal.pone.0143896. eCollection 2015.

31.

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X.

Muczynski V, Bazaa A, Loubière C, Harel A, Cherel G, Denis CV, Lenting PJ, Christophe OD.

Blood. 2016 Feb 11;127(6):778-86. doi: 10.1182/blood-2015-05-647032. Epub 2015 Nov 25.

32.

Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis.

Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ.

J Thromb Haemost. 2015 Oct;13(10):1757-67. doi: 10.1111/jth.13120. Epub 2015 Sep 25. Review.

33.

Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.

Wohner N, Legendre P, Casari C, Christophe OD, Lenting PJ, Denis CV.

J Thromb Haemost. 2015 May;13(5):815-20. doi: 10.1111/jth.12885. Epub 2015 Mar 31.

34.

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.

Lenting PJ, Christophe OD, Denis CV.

Blood. 2015 Mar 26;125(13):2019-28. doi: 10.1182/blood-2014-06-528406. Epub 2015 Feb 23. Review.

35.

Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions.

Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S.

Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.

PMID:
25670067
36.

Of von Willebrand factor and platelets.

Bryckaert M, Rosa JP, Denis CV, Lenting PJ.

Cell Mol Life Sci. 2015 Jan;72(2):307-26. doi: 10.1007/s00018-014-1743-8. Epub 2014 Oct 9. Review.

37.

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.

Thromb Haemost. 2014 Nov;112(5):1014-23. doi: 10.1160/TH14-02-0148. Epub 2014 Jul 17.

PMID:
25030452
38.

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

Morioka Y, Casari C, Wohner N, Cho S, Kurata S, Kitano A, Christophe OD, Lenting PJ, Li R, Denis CV, Prévost N.

Blood. 2014 May 22;123(21):3344-53. doi: 10.1182/blood-2013-10-531392. Epub 2014 Apr 8.

39.

Platelet von Willebrand factor: sweet resistance.

Lenting PJ, Denis CV.

Blood. 2013 Dec 12;122(25):4006-7. doi: 10.1182/blood-2013-10-533174.

40.

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

Casari C, Berrou E, Lebret M, Adam F, Kauskot A, Bobe R, Desconclois C, Fressinaud E, Christophe OD, Lenting PJ, Rosa JP, Denis CV, Bryckaert M.

J Clin Invest. 2013 Dec;123(12):5071-81. doi: 10.1172/JCI69458. Epub 2013 Nov 25.

41.

Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.

Casari C, Du V, Wu YP, Kauskot A, de Groot PG, Christophe OD, Denis CV, de Laat B, Lenting PJ.

Blood. 2013 Oct 17;122(16):2893-902. doi: 10.1182/blood-2013-03-493312. Epub 2013 Aug 14.

42.

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.

Casari C, Lenting PJ, Christophe OD, Denis CV.

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013047. doi: 10.4084/MJHID.2013.047. Print 2013.

43.

On the versatility of von Willebrand factor.

Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ.

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013046. doi: 10.4084/MJHID.2013.046. Print 2013.

44.

Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target.

Lenting PJ, Denis CV, Wohner N.

Curr Vasc Pharmacol. 2013 Jul;11(4):448-56. Review.

PMID:
23905639
45.

Clearance of von Willebrand factor.

Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV.

J Thromb Haemost. 2013 Jun;11 Suppl 1:202-11. doi: 10.1111/jth.12226. Review.

46.

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, Morton CL, Davidoff AM, Nathwani AC.

Blood. 2013 Apr 25;121(17):3335-44. doi: 10.1182/blood-2012-10-462200. Epub 2013 Feb 20.

47.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Legendre P, Navarrete AM, Rayes J, Casari C, Boisseau P, Ternisien C, Caron C, Fressinaud E, Goudemand J, Veyradier A, Denis CV, Lenting PJ, Christophe OD.

Blood. 2013 Mar 14;121(11):2135-43. doi: 10.1182/blood-2012-09-456038. Epub 2013 Jan 18.

48.

Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance.

Kurdi M, Cherel G, Lenting PJ, Denis CV, Christophe OD.

PLoS One. 2012;7(9):e45111. doi: 10.1371/journal.pone.0045111. Epub 2012 Sep 25.

49.

von Willebrand factor: the old, the new and the unknown.

Lenting PJ, Casari C, Christophe OD, Denis CV.

J Thromb Haemost. 2012 Dec;10(12):2428-37. doi: 10.1111/jth.12008. Review.

50.

A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor.

Navarrete AM, Casari C, Legendre P, Marx I, Hu JR, Lenting PJ, Christophe OD, Denis CV.

Blood. 2012 Sep 27;120(13):2723-32. Epub 2012 Aug 20.

Supplemental Content

Loading ...
Support Center